Status of treatment of depression

Southern Medical Journal

Volumn 92, Issue 9, 1999, Pages 846-856

  Broquet, Karen E ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DEPRESSION; DIAGNOSTIC APPROACH ROUTE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; HUMAN; PSYCHIATRIC TREATMENT; SIDE EFFECT;

EID: 0032857153     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199909000-00001     Document Type: Article

References (68)

1. Depression Guideline Panel: Depression in Primary Care: Volume 2. Treatment of Major Depression. Clinical Practice Guideline, No 5. Rockville, Md, US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication No. 93-0551, April 1993
2. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC, American Psychiatric Association, 4th Ed, 1994
3. Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
4. Thase ME: Relapse and recurrence in unipolar major depression: short-term and long-term approaches. J Clin Psychiatry 1990; 51 (suppl):51-57
5. National Institute of Mental Health Consensus Development Conference Statement: Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 1985; 142:469-476
6. Sargeant JK, Bruce ML, Florio LP, et al: Factors associated with 1-year outcome of major depression in the community. Arch Gen Psychiatry 1990; 47:519-526
7. Blair-West GW, Mellsop GW, Eyeson-Annan ML: Down-rating suicide risk in major depression. Acta Psychiatr Scand 1997; 95:259-263
8. Gruenberg A, Goldstein R: Depressive disorders. Psychiatry. Tasman A, Kay J, Lieberman J (eds). Philadelphia, WB Saunders Co, 1997, pp 990-1019
9. Venlafaxine [package insert]. Philadelphia, Wyeth Laboratories, 1996
10. Burrows G, Kremer C: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol 1997; 17(suppl 1):34S-39S
11. Pies R: Handbook of Essential Psychopharmacology. Washington, DC, American Psychiatric Press, 1998, pp 1-56
12. Potter W, Manji H, Rudorfer M: Tricyclics and tetracyclics. The American Psychiatric Press Textbook of Psychopharmacology. Schatzberg A, Nemeroff C (eds). Washington, DC, American Psychiatric Press, 2nd Ed, 1998, pp 199-218
13. Thayssen P, Bjerre M, Kragh-Sorenson M, et al: Cardiovascular effect of imipramine and nortriptyline in elderly patients. Psychopharmacology (Berl) 1981; 74:360-364
14. Golden R, Dawkins K, Nicholas L, et al: The American Psychiatric Press Textbook of Psychopharmacology. Schatzberg A, Nemeroff C (eds). Washington DC, American Psychiatric Press, 2nd Ed, 1998, pp 251-269
15. Tollefson G, Rosenbaum J: Selective serotonin reuptake inhibitors. The American Psychiatric Press Textbook of Psychopharmacology. Schatzberg A, Nemeroff C (eds). Washington, DC, American Psychiatric Press, 2nd Ed, 1998, pp 219-237
16. Andrews J, Nemeroff C: Contemporary management of depression. Am J Med 1994; 97(suppl 6A):24S-32S
17. Roose S, Glassman A, Attia E, et al: Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am JPsychiatry 1994; 151:1735-1739
18. Keller M, Boland R: Antidepressants. Psychiatry. Tasman A, KayJ, Lieberman J (eds). Philadelphia, WB Saunders Co, 1997, pp 1606-1639
19. Preskorn S, Janicak P, Davis J, et al: Advances in the pharmacotherapy of depressive disorders. Principles and Practice of Psychopharmacotherapy Update. Retford DC (ed). Baltimore, Williams & Wilkins Co, Vol 1, 1995
20. Walker PW, Cole JO, Gardner EA, et al: Improvement in fluoxetine associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1991; 52:66-68
21. Cohen AJ: Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment (Letter). J Clin Psychiatry 1992; 53:174
22. Balogh S, Hendricks SE, Kang J: Treatment of fluoxetine-induced anorgasmia with amantadine (Letter). J Clin Psychiatry 1992; 53:212-213
23. Jacobsen FM: Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53:119-122
24. Crewe HK, Lennard MS, Tucker GT, et al: The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-265
25. Nightingale S: Fluoxetine labeling revised to identify phenytoin interaction and to recommend against use in nursing mothers. JAMA 1994; 14:1067
26. Nefazodone [package insert]. East Syracuse, NY, Bristol-Myers Squibb, 1996
27. Rickels K, Robinson DS, Schweizer E, et al: Nefazodone: aspects of efficacy. J Clin Psychopharmacol 1995; 56(suppl 6):43-46
28. Kent JM, Gorman JM: Venlafaxine. American Psychiatric Press Textbook of Psychopharmacology. Schatzberg A, Nemeroff C (eds). Washington, DC, American Psychiatric Press, 2nd Ed, 1998, pp 301-306
29. Clerc GE, Ruimy P, Verdeau-Palles J: A double blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9:139-143
30. Kasper S, Prashak-Reider N, Tauscher J, et al: A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997; 4:251-264
31. Montgomery SA: Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995; 10(suppl 4):37-45
32. Mirtazapine [package insert]. West Orange, NJ, Organon, 1996
33. Krishnan KR: Monoamine oxidase inhibitors. The American Psychiatric Press Textbook of Psychopharmacology. Schatzberg A, Nemeroff C (eds). Washington, DC, American Psychiatric Press, 2nd Ed, 1998, pp 239-249
34. St. John's Wort. Med Lett Drugs Ther 1997; 39:107-108
35. Linde K, Ramirez G, Mulrow C, et al: St. John's Wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313:253-258
36. Volz HP: Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry 1997; 30(suppl):72-76
37. Ernst E, Rand J, Stevinson C: Complementary therapies for depression. Arch Gen Psychiatry 1998; 55:1026-1032
38. Yamishita I, Asano Y: Tricyclic antidepressants: therapeutic plasma levels. Psychopharmacol Bull 1979; 15:40-41
39. Yonkers KA, Kando JC, Cole JO, et al: Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149:587-595
40. Pastuszak A, Schick-Boschetto B, Zuber C, et al: Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269:2246-2248
41. Altshuler L, Cohen L, Szuba M, et al: Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592-606
42. Eggermont E: Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 1973; 2:680
43. Webster PAC: Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973; 2:318-319
44. Schimmel MS, Katz EZ, Shaag Y, et al: Toxic neonatal effects following maternal clomipramine therapy. Clin Toxicol 1991; 29:479-484
45. Cowe L, Lloyd DJ, Dawling S: Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ 1982; 284:1837-1838
46. Chambers CD, Johnson KA, Dick LM, et al: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015
47. Kulin NA, Pastuszak A, Sage SR, et al: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279:609-610
48. Nulman I, Rovet J, Stewart DE, et al: Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336:258-262
49. Misri S, Sivertz K: Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21:157-171
50. Heinonen OP, Slone D, Shapiro S: Birth Defects and Drugs in Pregnancy. Littleton, Mass, Publishing Services Group, 1977
51. Poulson E, Robeson JM: Effect of phenylzine and some related compounds on pregnancy. J Endorrinol 1964; 30:205-215
52. Wisner KL, Perel JM, Findling RL: Antidepressant treatment during breastfeeding. Am JPsychiatry 1996; 153:1132-1137
53. Stowe ZN, Owens MJ, Landry JC, et al: Sertraline and desmethylsertraline in human breast milk and nursing infants. AmJPsychiatry 1997; 154:1255-1260
54. Brent NB, Wisner KL: Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr 1998; 37:41-44
55. Mammen OK, Perel JM, Rudolph G, et al: Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58:100-103
56. Briggs GG, Samson JH, Ambrose PJ, et al: Excretion of bupropion in breast milk. Ann Pharmacother 1993; 27:431-433
57. Fluoxetine [package insert]. Indianapolis, Dista Products Co, 1995
58. Elkin I, Shea TM, Watkins JT, et al: National Institute of Mental Health treatment of depression collaborative research program. general effectiveness of treatments. Arch Gen Psychiatry 1989; 46:971-982
59. Frank E, Kupfer DJ, Perel JM, et al: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-1099
60. American Psychiatric Association: Practice guideline for major depressive disorder in adults. Am J Psychiatry 1993; 150(suppl 4):1-26
61. Schou M: Lithium and treatment-resistant depressions: a review. Lithium 1990; 1:3-8
62. Joffe RT, Singer W, Levitt AJ, et al: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387-393
63. Wharton RN, Perel JM, Dayton PG, et al: A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971; 127:1619-1625
64. Greenberg PE, Stiglin LE, Finkelstein SN, et al: The economic burden of depression in 1990. J Clin Psychiatry 1993; 54:405-418
65. Montgomery SA, Brown RE, Clark M: Economic analysis of treating depression with nefazodone vs imipramine. Br J Psychiatry 1996; 168:768-771
66. Lapierre Y, Bentkover J, Schainbaum S, et al: Direct cost of depression: analysis of treatment costs of paroxetine versus imipramine in Canada. Can J Psychiatry 1995; 40:370-377
67. Revicki DA, Brown RE, Keller MB, et al: Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1977; 58:47-58
68. McFarland BH: Cost-effectiveness considerations for managed care systems: treating depression in primary care. Am J Med 1994; 97(suppl 6A):47S-57S